UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 5.104

Sortiert nach

Discovery of a subnanomolar and selective spirocyclic agonist of the glucocorticoid receptor

European journal of medicinal chemistry, 2019-01, Vol.161, p.354-363

2019

Link zum Volltext

Verfügbarkeit prüfen

Recent Advances in Indazole-Containing Derivatives: Synthesis and Biological Perspectives

Molecules (Basel, Switzerland), 2018-10, Vol.23 (11), p.2783

2018

Link zum Volltext

Verfügbarkeit prüfen

Niraparib: First Global Approval

Drugs (New York, N.Y.), 2017-06, Vol.77 (9), p.1029-1034

Scott, Lesley J.

2017

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a 3‑(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

Journal of medicinal chemistry, 2017-04, Vol.60 (7), p.2983-2992

2017

Link zum Volltext

Verfügbarkeit prüfen

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

Osteoarthritis and cartilage, 2017-10, Vol.25 (10), p.1598-1606

2017

Link zum Volltext

Verfügbarkeit prüfen

Rh(III)/Cu(II)-cocatalyzed synthesis of 1H-indazoles through C-H amidation and N-N bond formation

Journal of the American Chemical Society, 2013-06, Vol.135 (24), p.8802-8805

2013

Link zum Volltext

Verfügbarkeit prüfen

Highly efficient synthesis of triazolo[1,2- a]indazole-triones and novel spiro triazolo[1,2- a]indazole-tetraones under solvent-free conditions

Tetrahedron, , Vol.67 (2), p.390-400

Link zum Volltext

Verfügbarkeit prüfen

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Journal of medicinal chemistry, 2008-09, Vol.51 (18), p.5522-5532

2008

Link zum Volltext

Verfügbarkeit prüfen

“Zombie” Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York

The New England journal of medicine, 2017-01, Vol.376 (3), p.235-242

2017

Link zum Volltext

Verfügbarkeit prüfen

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

Journal of clinical oncology, 2015-01, Vol.33 (2), p.172-179

2015

Link zum Volltext

Verfügbarkeit prüfen

Ocular Drug Delivery Nanowafer with Enhanced Therapeutic Efficacy

ACS nano, 2015-02, Vol.9 (2), p.1749-1758

2015

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of indazole motifs and their medicinal importance: An overview

European journal of medicinal chemistry, 2015-01, Vol.90, p.707-731

2015

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors

Journal of medicinal chemistry, 2009-11, Vol.52 (22), p.7170-7185

2009

Link zum Volltext

Verfügbarkeit prüfen

Switching on prodrugs using radiotherapy

Nature chemistry, 2021-08, Vol.13 (8), p.805

2021

Link zum Volltext

Verfügbarkeit prüfen

Indazole derivatives and their therapeutic applications: a patent review (2013-2017)

Expert opinion on therapeutic patents, 2018-06, Vol.28 (6), p.441-453

2018

Link zum Volltext

Verfügbarkeit prüfen

Recent Advances in the Chemistry of Indazoles

European Journal of Organic Chemistry, 2008-08, Vol.2008 (24), p.4073-4095

2008

Link zum Volltext

Verfügbarkeit prüfen

Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity

European journal of medicinal chemistry, 2021-01, Vol.209, p.112911-112911, Article 112911

2021

Link zum Volltext

Verfügbarkeit prüfen

The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo

European journal of medicinal chemistry, 2020-02, Vol.187, p.111968-111968, Article 111968

2020

Link zum Volltext

Verfügbarkeit prüfen

Chemistry and biology of indoles and indazoles: a mini-review

Mini reviews in medicinal chemistry, 2013-10, Vol.13 (12), p.1792

2013

Link zum Volltext

Verfügbarkeit prüfen

A review of poly(ADP-ribose)polymerase-1 (PARP1) role and its inhibitors bearing pyrazole or indazole core for cancer therapy

Biochemical pharmacology, 2024-03, Vol.221, p.116045-116045, Article 116045

2024

Link zum Volltext

Verfügbarkeit prüfen

Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity

Bioorganic chemistry, 2019-02, Vol.82, p.340-359

2019

Link zum Volltext

Verfügbarkeit prüfen

Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer

European journal of medicinal chemistry, 2021-03, Vol.214, p.113219, Article 113219

2021

Link zum Volltext

Verfügbarkeit prüfen

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

The New England journal of medicine, 2019-12, Vol.381 (25), p.2391-2402

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 5.104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.799)
Mit Volltextzugriff
(4.345)

Publikationsform

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(39)

Menü

Weitere Dienste

Einstellungen

Discovery of a subnanomolar and selective spirocyclic agonist of the glucocorticoid receptor

Recent Advances in Indazole-Containing Derivatives: Synthesis and Biological Perspectives

Niraparib: First Global Approval

Discovery of a 3‑(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

Rh(III)/Cu(II)-cocatalyzed synthesis of 1H-indazoles through C-H amidation and N-N bond formation

Highly efficient synthesis of triazolo[1,2- a]indazole-triones and novel spiro triazolo[1,2- a]indazole-tetraones under solvent-free conditions

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

“Zombie” Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

Ocular Drug Delivery Nanowafer with Enhanced Therapeutic Efficacy

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Synthesis of indazole motifs and their medicinal importance: An overview

Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors

Switching on prodrugs using radiotherapy

Indazole derivatives and their therapeutic applications: a patent review (2013-2017)

Discovery of Entrectinib: A New 3‑Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c‑ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Recent Advances in the Chemistry of Indazoles

Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity

The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo

Chemistry and biology of indoles and indazoles: a mini-review

A review of poly(ADP-ribose)polymerase-1 (PARP1) role and its inhibitors bearing pyrazole or indazole core for cancer therapy

Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity

Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Suchergebnisse filtern